Timber Pharmaceuticals Stock Price, News & Analysis (NYSE:TMBR) Add Compare Share Share Today's Range N/A50-Day Range$0.34▼$3.0352-Week Range N/AVolume26,307 shsAverage Volume511,937 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media About Timber Pharmaceuticals Stock (NYSE:TMBR)Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.Read More TMBR Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)December 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 21, 2023 | seekingalpha.comMVST, FBIO and VTVT among mid-day moversNovember 17, 2023 | msn.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 16, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.September 18, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceAugust 29, 2023 | 247wallst.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 28, 2023 | msn.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 21, 2023 | benzinga.comTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | markets.businessinsider.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | msn.comTimber to be taken private by LEO Pharma, stock soars 100%August 21, 2023 | investorplace.comWhy Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?August 21, 2023 | markets.businessinsider.comUS Stocks Mostly Higher; Nasdaq Jumps 100 PointsAugust 21, 2023 | marketwatch.comTimber Pharmaceuticals Shares Soar on Takeover by LEO PharmaAugust 21, 2023 | benzinga.comWhy Timber Pharmaceuticals Stock Is Skyrocketing TodayAugust 21, 2023 | finance.yahoo.comLEO Pharma Signs Agreement to Acquire Timber PharmaceuticalsAugust 21, 2023 | finance.yahoo.comTimber Pharmaceuticals to be Acquired by LEO PharmaAugust 15, 2023 | morningstar.comTimber Pharmaceuticals Inc Ordinary SharesJuly 3, 2023 | finance.yahoo.comTimber Pharmaceuticals Discloses Communication From NYSE AmericanJune 5, 2023 | msn.comTimber Pharmaceuticals Soars as FDA Removes HurdleJune 5, 2023 | msn.comTimber Pharmaceuticals stock jumps as much as 83% after FDA waiver to forgo rodent studyJune 5, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001May 15, 2023 | finance.yahoo.comTimber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial ResultsSee More Headlines Receive TMBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TMBR CUSIPN/A CIK1504167 Webwww.timberpharma.com Phone(973) 314-9577FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-511.45% Return on Assets-180.93% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / BookN/AMiscellaneous Outstanding Shares3,430,000Free Float3,378,000Market Cap$1.21 million OptionableNot Optionable Beta0.03 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. John Koconis M.B.A. (Age 53)Chairman, CEO & President Comp: $570.19kMr. Joseph Lucchese (Age 56)Executive VP, CFO, Treasurer & Secretary Comp: $542.3kDr. Alan Mendelsohn M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $507.16kKey CompetitorsAvalo TherapeuticsNASDAQ:AVTXChina SXT PharmaceuticalsNASDAQ:SXTCAthersysNASDAQ:ATHXKintara TherapeuticsNASDAQ:KTRASciSparcNASDAQ:SPRCView All CompetitorsInstitutional OwnershipTudor Investment Corp Et AlBought 251,037 shares on 11/16/2023Ownership: 7.319%View All Institutional Transactions TMBR Stock Analysis - Frequently Asked Questions Should I buy or sell Timber Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares. View TMBR analyst ratings or view top-rated stocks. What is Timber Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12 month target prices for Timber Pharmaceuticals' stock. Their TMBR share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. View analysts price targets for TMBR or view top-rated stocks among Wall Street analysts. When did Timber Pharmaceuticals' stock split? Timber Pharmaceuticals's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Timber Pharmaceuticals' major shareholders? Timber Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Tudor Investment Corp Et Al (7.32%). Insiders that own company stock include Alan Mendelsohn, Edward J Sitar, John Koconis and Tardimed Sciences Llc. View institutional ownership trends. How do I buy shares of Timber Pharmaceuticals? Shares of TMBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:TMBR) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Timber Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.